Home/ Applications/ Cell Therapy & ATMP Manufacturing

SeamlessBio — Solutions by Application

Cell Therapy & ATMP Manufacturing — FBS, Human Serum & hPL Supply Guide

Q: Why does FBS Tet-Free matter specifically for CAR-T development?

Standard FBS contains tetracycline residues at 10–100 ng/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible gene expression systems — widely used for inducible CAR construct expression and lentiviral packaging cell lines — are suppressed by tetracycline at concentrations as low as 1–10 ng/mL. Standard FBS can partially or completely suppress transgene induction in these systems, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free <10 ng/mL eliminates this interference and is the only correct grade for any Tet-regulated ATMP application.

Q: Can I use standard FBS for Phase I/II CAR-T trials?

EMA/410/01 discourages FBS in clinical ATMP manufacturing and requires explicit justification if animal-derived ancillary materials are used. For Phase I/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional xenogenic sensitisation safety testing documentation. For GMP-phase manufacturing, SeamlessBio recommends transitioning to Human Serum AB OTC Male. Where FBS is still required for non-clinical studies or specific process steps, the FBS grade must be specified — standard FBS is not acceptable in ATMP contexts.

Q: What is the difference between hPL and Human Serum for T cell expansion?

Human Platelet Lysate (hPL) is produced by freeze-thaw lysis of pooled platelets — it releases a very high concentration of platelet-derived growth factors (PDGF, TGF-β, FGF, EGF, IGF-1) with no serum immunoglobulins. hPL is particularly effective for MSC expansion (typically 3–5× higher proliferation rates vs FBS) and has been used in xeno-free T cell expansion protocols. Human Serum AB OTC Male is the established standard for CAR-T T cell expansion — with extensive clinical validation data. hPL may offer advantages in specific protocols but requires its own process validation. Both are available from SeamlessBio with EU donor documentation.

Q: How long can I reserve a Human Serum AB OTC Male lot for a CAR-T programme?

SeamlessBio holds reserved Human Serum AB OTC Male lots for up to 6 months during process development and clinical manufacturing campaigns — no cost during the evaluation phase, with flexible call-off volumes from 100 mL to bulk. For Phase I autologous CAR-T manufacturing typically requiring 3–10 patient batches, a lot reservation of 500 mL to 2 L is usually sufficient. Extended reservation beyond 6 months is available on request for multi-year ATMP development programmes.

Q: Which documentation does SeamlessBio provide for EMA ATMP submissions?

For Human Serum AB products: CoA, Certificate of Origin (EU Blood Directive-qualified donor centres), viral testing panel per lot (HIV-1/2 NAT, HBV NAT, HCV NAT, CMV, EBV, Parvovirus B19), Ph. Eur. 5.2.12 declaration on request, and Eudralex Vol. 4 Part IV compliance documentation. For FBS specialty grades: CoA, CoO, TSE/BSE statement per EMA CHMP/BWP, mycoplasma testing, BVDV testing, gamma irradiation certificate where applicable. The full documentation package is assembled per lot and provided with each shipment.

Q: Is Human Platelet Lysate (hPL) suitable for clinical-grade MSC expansion?

Yes — hPL is EMA-accepted for clinical-grade MSC expansion and is specified in several published GMP protocols for MSC manufacturing. EMA's Committee for Advanced Therapies (CAT) has reviewed hPL as a xeno-free FBS alternative in MSC-based ATMP manufacturing. SeamlessBio supplies hPL from pooled EU donor platelets with full pathogen screening documentation (HIV, HBV, HCV, Parvovirus B19, CMV, EBV) and batch consistency testing. For clinical applications, we recommend requesting lot-specific growth promotion test data alongside the standard CoA.

Advanced therapy medicinal products — CAR-T cells, iPSC-derived therapies, gene-modified cell products — place exceptionally high demands on biological raw materials. Serum lots must be pre-screened and reserved months in advance, endotoxin must be minimal, and tetracycline-free grades are mandatory for inducible expression systems. SeamlessBio supplies specialty FBS, human serum, hPL and bioprocessing bags for ATMP manufacturing with EU supply chain, batch reservation, and full EMA documentation.

⚠ EMA/410/01 — The Regulatory Baseline for Serum in ATMP Manufacturing: EMA guideline EMA/410/01 explicitly discourages the use of FBS in the manufacture of ATMPs including CAR-T cell products. Human serum is the preferred ancillary material. Ph. Eur. 5.2.12 documentation is required for all human-derived ancillary materials in GMP-phase manufacturing. SeamlessBio provides full Ph. Eur. 5.2.12 and Eudralex Vol. 4 Part IV documentation on request. Where FBS is still used (research phase, non-clinical studies), FBS Tet-Free, Ultra Low IgG and Low Endotoxin grades are mandatory — not standard FBS.

Human Serum AB OTC Male

GMP gold standard for ex vivo T cell expansion. AB type — no anti-A/B agglutination. Male donors — no hormonal variability. Off-the-clot — maximum platelet growth factors (PDGF, EGF, TGF-β). EMA/410/01 preferred ancillary material.

Human Platelet Lysate (hPL)

Xeno-free FBS alternative for MSC expansion and T cell culture. No animal-derived components. Higher MSC proliferation rate than FBS. GMP documentation available. EU donor network.

FBS Tet-Free <10 ng/mL

Mandatory for Tet-On/Tet-Off inducible CAR construct expression and lentiviral packaging systems. Tetracycline residues at even ng/mL levels suppress transgene induction — the most common cause of failed inducible CAR-T constructs.

FBS Ultra Low IgG <5 µg/mL

For research-phase T cell activation, ADCC assay development, and flow cytometry readouts. Bovine IgG in standard FBS occupies FcγR on T cells and APCs — directly interfering with CD3/CD28 activation signals and ADCC measurement.

EMA/410/01 — Why Human Serum is the ATMP Standard

EMA guideline EMA/410/01 (Guidelines on the use of bovine serum in the manufacture of human biological medicinal products) explicitly discourages FBS in clinical ATMP manufacturing. The regulatory concern is twofold: FBS introduces bovine xenogenic antigens that can sensitise expanded T cells and generate anti-bovine immune responses in the patient following infusion, and FBS lot variability introduces process variability that is unacceptable in GMP manufacturing.

Human Serum AB Male OTC is the gold standard for ex vivo T cell expansion in CAR-T manufacturing. Each specification is mechanistically justified:

AB type: Prevents anti-A/B antibody-mediated agglutination and lysis of residual red blood cells in donor T cell expansion cultures — donor T cells can be any blood group.

Male donors only: Eliminates hormonal lot-to-lot variability from the female menstrual cycle. Oestrogen and progesterone affect T cell activation thresholds and cytokine production — introducing expansion yield variation between manufacturing runs.

Off-the-clot: Preserves maximum platelet-derived growth factors (PDGF, EGF, TGF-β, IGF-1) released during clot formation. These factors directly amplify T cell activation signals and ex vivo expansion yield. Centrifuged or platelet-poor preparations have significantly lower growth factor content.

For fully xeno-free protocols, rHSA Premium Grade replaces albumin supplementation and human platelet lysate (hPL) replaces serum entirely for MSC and some T cell expansion applications.

Key products by ATMP type

Human Serum AB OTC Male — CAR-T ex vivo expansion
Human Serum AB HI — T cell activation, QC ELISpot
Human Platelet Lysate (hPL) — Xeno-free MSC, T cell expansion
rHSA Premium Grade — Xeno-free media supplement, cryopreservation
FBS Tet-Free <10 ng/mL — Inducible CAR, lentiviral packaging
FBS Ultra Low IgG <5 µg/mL — Research T cell activation, ADCC
FBS Very Low Endotoxin ≤1 EU/mL — ELISpot, PBMC potency assays
FBS ES Cell Pre-Tested — iPSC culture, reprogramming

Key Reagents for ATMP Applications — Complete Specification Table

Product	Grade / Specification	ATMP Application	Why This Grade
Human Serum AB OTC Male	Type AB, male donors, off-the-clot, native	CAR-T, TCR-T, NK cell ex vivo expansion. iPSC-derived T cell products.	EMA/410/01 preferred. Max platelet growth factors. No anti-A/B. No hormonal variability between lots.
Human Serum AB HI	Type AB, heat inactivated 56°C/30 min	T cell activation phase (complement-sensitive protocols). PBMC-based QC potency assays. ELISpot.	Complement destroyed — prevents lysis of activated T cells and PBMC during culture and assay.
Human Platelet Lysate (hPL)	Pooled, pathogen-screened, EU donors	Xeno-free MSC expansion. T cell expansion where full xeno-free protocol required. GMP-transition preferred FBS alternative.	No animal-derived components. 3–5× higher MSC proliferation vs FBS in some protocols. EMA Annex I xeno-free compliant.
rHSA Premium Grade	Rice-expressed, ≥99% purity, ≤1 EU/mg, ISO 13485	Albumin supplement in defined xeno-free T cell or iPSC media. Formulation buffer for harvest and GMP cryopreservation.	No donor variability. No blood-borne pathogen risk. Defined composition. GMP documentation package available.
FBS Tet-Free <10 ng/mL	Tetracycline <10 ng/mL — tested per lot	Tet-On/Tet-Off inducible CAR construct expression. Lentiviral packaging cell line culture (Tet-regulatable packaging systems). AAV Tet-inducible production.	Tetracycline at even ng/mL residues suppress Tet-responsive promoters — the most common hidden cause of failed inducible transgene expression in CAR-T development.
FBS Ultra Low IgG <5 µg/mL	IgG <5 µg/mL — chromatographic depletion	Research-phase T cell activation screening. ADCC potency assay development. Flow cytometry with Fc-receptor-bearing cells. Hybridoma screening.	Standard FBS contains 200–800 µg/mL bovine IgG that occupies FcγR on T cells and APCs — directly interfering with CD3/CD28 activation signals and masking ADCC readout.
FBS Very Low Endotoxin ≤1 EU/mL	≤1 EU/mL — LAL tested per lot	ELISpot potency assays, PBMC-based release testing, NK cell functional assays, monocyte/macrophage-sensitive primary cell culture.	Endotoxin activates monocytes via TLR4 → non-specific IFN-γ/TNF-α background in ELISpot and multiplex cytokine assays — masking antigen-specific CAR-T potency signal.
FBS ES Cell Pre-Tested	Oct4/Sox2/Nanog validated, <5% spontaneous differentiation per lot	iPSC reprogramming, feeder-dependent iPSC maintenance, embryoid body formation, hematopoietic differentiation for iPSC-derived CAR-T.	Standard FBS drives spontaneous iPSC differentiation within 1–2 passages — lot not screened for pluripotency maintenance. ES Cell Pre-Tested lots validated per lot before release.
FBS Gamma Irradiated ≥25 kGy	Gamma irradiated ISO 11137	Enhanced viral safety margin for ATMP lentiviral vector production in BSL-2 facilities. Additional pathogen clearance step documentation.	Gamma irradiation provides additional assurance against viral contamination in FBS — relevant for viral vector production where contamination would compromise product safety.

CAR-T Manufacturing — Reagent Requirements by Phase

Phase	Process Step	Recommended Product	Key Note
R&D — Process Development	T cell isolation, activation screening, vector optimisation	FBS Ultra Low IgG <5 µg/mL	Low IgG prevents FcR competition in T cell activation assays — cost-effective for high-throughput screening before GMP commitment
R&D → GMP — T Cell Activation	CD3/CD28 stimulation, IL-2 supplementation, pre-expansion	Human Serum AB OTC Male (or HI where complement must be inactivated)	OTC: maximum platelet growth factors for activation signal amplification. HI: when complement activation during stimulation is problematic.
GMP — Ex Vivo T Cell Expansion	Large-scale CAR-T expansion in static bags or rocker bioreactor	Human Serum AB OTC Male — 5–10%	EMA/410/01 preferred ancillary material. Ph. Eur. 5.2.12 documentation included on request. Batch reservation for full Phase I campaign.
GMP — Bioreactor Expansion	Rocking bag scale-up (0.5–50 L)	Rocker Bags 0.5–200 L	Corning and HyPerforma platform compatible. ISO 13485. Gamma sterilised ≥25 kGy ISO 11137. Custom port configurations.
GMP — Xeno-Free / Serum-Free Protocols	Defined serum-free T cell expansion medium	rHSA Premium Grade as albumin supplement	For fully xeno-free GMP protocols. rHSA replaces albumin supplementation with defined, lot-consistent animal-free alternative.
GMP — Media Preparation & Storage	Media preparation, buffer formulation	2D Single-Use Bags 150 mL–50 L	Closed system — no cleaning validation. GMP documentation. Drop-in for Sartorius Flexboy. ISO 13485 Germany.
GMP — Harvest & Formulation	Cell harvest, wash, formulation in cryo medium	2D Single-Use Bags + rHSA or native HSA in formulation buffer	Closed transfer into gamma-sterilised bags. HSA/rHSA as protein stabiliser in formulation buffer — prevents cell adsorption to surfaces.
QC — Release Testing	Cytotoxicity, ELISpot, ADCC potency assay	FBS VLE ≤1 EU/mL + Human Serum AB HI	VLE FBS for ELISpot background reduction. Human Serum AB HI for PBMC-based release assays where complement-free matrix required.

ATMP Supply Chain Requirements — What SeamlessBio Provides

ATMP manufacturing has unique supply chain demands that differ fundamentally from research use. A reagent lot change mid-process can invalidate months of process development work and require complete process re-validation.

Requirement	SeamlessBio Solution	Regulatory Relevance
Batch reservation	Reserve a dedicated lot from process development through clinical manufacturing. Up to 6 weeks cost-free during evaluation; extended reservation for full Phase I/II campaign on request.	GMP process validation — same lot throughout manufacturing campaign required to avoid re-validation
Extended lot testing	Mycoplasma, sterility, BVDV, HAV, B19 parvovirus, extended adventitious agent panels available on request through supply network.	ICH Q5A — viral safety of biological raw materials in ATMP manufacturing
EU origin and EU logistics	EU-sourced human serum from EU Blood Directive-qualified donor centres. Germany-based logistics — 24–48 hour cold-chain delivery DACH and EU.	EMA ATMP submissions: EU-origin material simplifies regulatory documentation vs non-EU-origin
Ph. Eur. 5.2.12 documentation	Full Ph. Eur. 5.2.12 declaration for human-derived ancillary materials on request. Eudralex Vol. 4 Part IV compliance documentation.	Mandatory for human-derived ancillary materials in GMP ATMP Phase I/II manufacturing
No minimum order quantity	100 mL for validation through to bulk volumes for clinical manufacturing — same supplier, same lot.	Process consistency from validation scale through clinical scale without supplier change
FBS → Human Serum transition support	Validated stepwise transition protocol: 50% FBS/50% Human Serum → 25%/75% → 100% Human Serum over 3 weeks with monitoring parameters.	EMA/410/01 compliance — transition from FBS-based research process to human serum for clinical manufacturing

Frequently Asked Questions

Why does FBS Tet-Free matter specifically for CAR-T development?

Standard FBS contains tetracycline residues at 10–100 ng/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible gene expression systems — widely used for inducible CAR construct expression and lentiviral packaging cell lines — are suppressed by tetracycline at concentrations as low as 1–10 ng/mL. Standard FBS can partially or completely suppress transgene induction in these systems, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free <10 ng/mL eliminates this interference and is the only correct grade for any Tet-regulated ATMP application.

Can I use standard FBS for Phase I/II CAR-T trials?

EMA/410/01 discourages FBS in clinical ATMP manufacturing and requires explicit justification if animal-derived ancillary materials are used. For Phase I/II CTA submissions to EMA, human serum or defined xeno-free media are the expected standard. FBS-based processes will face regulatory questions and may require additional xenogenic sensitisation safety testing documentation. For GMP-phase manufacturing, SeamlessBio recommends transitioning to Human Serum AB OTC Male. Where FBS is still required for non-clinical studies or specific process steps, the FBS grade must be specified — standard FBS is not acceptable in ATMP contexts.

What is the difference between hPL and Human Serum for T cell expansion?

Human Platelet Lysate (hPL) is produced by freeze-thaw lysis of pooled platelets — it releases a very high concentration of platelet-derived growth factors (PDGF, TGF-β, FGF, EGF, IGF-1) with no serum immunoglobulins. hPL is particularly effective for MSC expansion (typically 3–5× higher proliferation rates vs FBS) and has been used in xeno-free T cell expansion protocols. Human Serum AB OTC Male is the established standard for CAR-T T cell expansion — with extensive clinical validation data. hPL may offer advantages in specific protocols but requires its own process validation. Both are available from SeamlessBio with EU donor documentation.

How long can I reserve a Human Serum AB OTC Male lot for a CAR-T programme?

SeamlessBio holds reserved Human Serum AB OTC Male lots for up to 6 months during process development and clinical manufacturing campaigns — no cost during the evaluation phase, with flexible call-off volumes from 100 mL to bulk. For Phase I autologous CAR-T manufacturing typically requiring 3–10 patient batches, a lot reservation of 500 mL to 2 L is usually sufficient. Extended reservation beyond 6 months is available on request for multi-year ATMP development programmes.

Which documentation does SeamlessBio provide for EMA ATMP submissions?

For Human Serum AB products: CoA, Certificate of Origin (EU Blood Directive-qualified donor centres), viral testing panel per lot (HIV-1/2 NAT, HBV NAT, HCV NAT, CMV, EBV, Parvovirus B19), Ph. Eur. 5.2.12 declaration on request, and Eudralex Vol. 4 Part IV compliance documentation. For FBS specialty grades: CoA, CoO, TSE/BSE statement per EMA CHMP/BWP, mycoplasma testing, BVDV testing, gamma irradiation certificate where applicable. The full documentation package is assembled per lot and provided with each shipment.

Is Human Platelet Lysate (hPL) suitable for clinical-grade MSC expansion?

Yes — hPL is EMA-accepted for clinical-grade MSC expansion and is specified in several published GMP protocols for MSC manufacturing. EMA's Committee for Advanced Therapies (CAT) has reviewed hPL as a xeno-free FBS alternative in MSC-based ATMP manufacturing. SeamlessBio supplies hPL from pooled EU donor platelets with full pathogen screening documentation (HIV, HBV, HCV, Parvovirus B19, CMV, EBV) and batch consistency testing. For clinical applications, we recommend requesting lot-specific growth promotion test data alongside the standard CoA.

← All Application Guides Overview

Batch Reservation & GMP Documentation for ATMP Programmes

Reserve a validated lot of Human Serum AB OTC Male for your full Phase I/II CAR-T or ATMP programme. Full Ph. Eur. 5.2.12 and Eudralex Vol. 4 Part IV documentation package available. Free test samples for process development. EU cold-chain delivery DACH and EU within 24–48 hours.
Email: info@seamlessbio.de | +49 851 37932226

Application Cell Therapy & ATMP Manufacturing